Pancreatic Cancer Research

ResearcherUniversity of RegensburgActive in the last 2 years

Frank Kullmann

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5575-1010; OpenAlex author ID A5112407666. Sources: OpenAlex.

Their work

Papers
13 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2011: 1 paper · 2012: none · 2013: 2 papers · 2014: none · 2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: 3 papers · 2025: none · 2026: 1 paper

Papers 13

  1. Growth differentiation factor-15 (GDF-15) in localized pancreatic adenocarcinoma treated with multiagent chemotherapy: a biomarker analysis from the NEOLAP tri… Co-author DOI 10.1016/j.esmogo.2025.100274↗
  2. Corrigendum to "Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a… Co-author DOI 10.1016/j.esmoop.2024.103463↗
  3. Corrigendum to "Prognostic and predictive value of CA 19-9 inlocally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a … Co-author DOI 10.1016/j.esmoop.2024.103705↗
  4. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Last author DOI 10.1016/s2468-1253(24)00197-3↗
  5. Adjuvant nab-Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial. Co-author DOI 10.1200/jco.22.01134↗
  6. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  7. Prognostic and predictive value of CA 19-9 in locally advanced pancreatic cancer treated with multiagent induction chemotherapy: results from a prospective, mu… Co-author DOI 10.1016/j.esmoop.2022.100552↗
  8. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEO… Co-author DOI 10.1016/s2468-1253(20)30330-7↗
  9. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  10. Patients with Advanced Pancreatic Cancer and Hyperbilirubinaemia: Review and German Expert Opinion on Treatment with nab-Paclitaxel plus Gemcitabine. First author DOI 10.1159/000441310↗
  11. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter, pooled analys… Co-author DOI 10.1007/s00432-012-1371-3↗
  12. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  13. KRAS mutation in metastatic pancreatic ductal adenocarcinoma: results of a multicenter phase II study evaluating efficacy of cetuximab plus gemcitabine/oxalipl… Co-author DOI 10.1159/000330194↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Volker Kunzmann · 9 shared papers, 2015–2026 · strength 1.17
  2. Volker Heinemann · 9 shared papers, 2013–2026 · strength 1.16
  3. Stefan Hubert Boeck · 9 shared papers, 2013–2026 · strength 1.16
  4. Thomas Jens Ettrich · 8 shared papers, 2018–2026 · strength 1.12
  5. Jens Thomas Siveke · 8 shared papers, 2015–2026 · strength 1.01
  6. Ingo Hartlapp · 5 shared papers, 2021–2026 · strength 0.76
  7. Uwe M. Martens · 5 shared papers, 2021–2026 · strength 0.76
  8. Hana Algül · 5 shared papers, 2021–2026 · strength 0.76
  9. Brigitte Kimmel · 4 shared papers, 2022–2026 · strength 0.67
  10. Friedrich Anger · 4 shared papers, 2022–2026 · strength 0.67
  11. Dirk Waldschmidt · 4 shared papers, 2021–2024 · strength 0.53
  12. Uwe Pelzer · 4 shared papers, 2021–2024 · strength 0.53
  13. Anke Reinacher‐Schick · 3 shared papers, 2018–2024 · strength 0.37
  14. Klara Dorman · 2 shared papers, 2023–2024 · strength 0.30
  15. Michael Haas · 3 shared papers, 2013–2023 · strength 0.24
  16. Steffen Ormanns · 1 shared paper, 2026 · strength 0.23
  17. Helmut Oettle · 2 shared papers, 2015–2024 · strength 0.21
  18. Dominik Paul Modest · 2 shared papers, 2013–2024 · strength 0.20
  19. Oliver Waidmann · 1 shared paper, 2024 · strength 0.16
  20. Maximilian Reichert · 1 shared paper, 2024 · strength 0.16
  21. Michael Geißler · 1 shared paper, 2024 · strength 0.16
  22. Patrick Michl · 1 shared paper, 2024 · strength 0.16
  23. Danmei Zhang · 1 shared paper, 2023 · strength 0.14
  24. Julia V. Mayerle · 1 shared paper, 2023 · strength 0.14
  25. Marcus Bahra · 1 shared paper, 2021 · strength 0.08

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.